Emcure Pharma Q1 FY27 Results (NSE: EMCURE)
Signal: Margin expansion
The read
The operating inflection remains intact: consolidated revenue rose 22.8% YoY to ₹25,804.47 million and EBITDA margin expanded 100bps to 20.7%, the second consecutive quarter of reported margin expansion after Q4FY26 was flat; PAT growth of 36.2% was operationally supported rather than driven by other income, while standalone margin at 25.1% highlights the stronger profitability of the parent business relative to the wider group.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹2,580.45 Cr | +22.8% | +4.5% |
| EBIT | ₹425.06 Cr | N/A | |
| Net profit | ₹292.49 Cr | +36.2% | |
| EPS | ₹15.5 | +41.9% | |
| EBIT margin | 20.7% |
P&L walk
Consolidated revenue increased 22.8% YoY to ₹25,804.47 million and EBITDA rose 25.8% to ₹5,345.7 million, with EBITDA margin expanding to 20.7%; PAT grew 36.2% to ₹2,924.93 million as finance costs fell sequentially and other income remained immaterial.
Segments
The Group reports only one segment, Pharmaceuticals, with revenue of ₹25,804.47 million and no segment-level result or asset split; the material standalone-versus-consolidated gap shows subsidiaries contributed ₹11,295.16 million of revenue and ₹923.85 million of profit for the period.
Key positives
- Consolidated revenue reached ₹25,804.47 million, up 22.8% YoY and 4.5% QoQ, sustaining the recent acceleration from Q4FY26's 16.7% YoY growth.
- EBITDA increased 25.8% YoY to ₹5,345.7 million and EBITDA margin expanded 100bps YoY to 20.7%, with raw-material intensity falling 195bps to 18.6% of revenue.
- Employee costs rose only 4.1% YoY to ₹4,094.95 million versus revenue growth of 22.8%, lowering employee-cost intensity to 15.9%.
- PAT of ₹2,924.93 million grew 36.2% YoY while other income was only ₹20.71 million, indicating limited dependence on non-operating income.
- Gennova became wholly owned effective July 21, 2026, increasing the Group's ownership of future subsidiary earnings and simplifying consolidation.
Key concerns
- Standalone revenue declined 1.1% QoQ to ₹14,509.31 million and standalone PAT fell 14.4% QoQ to ₹2,001.08 million, so the consolidated sequential momentum is being supported by subsidiaries.
- Consolidated finance costs rose 17.9% YoY to ₹315.36 million even though they fell 32.0% QoQ, leaving funding costs above the year-ago base.
- The filing does not disclose geography, product, volume, price/mix or R&D metrics, limiting diagnosis of the 22.8% revenue growth and margin expansion.
Research and educational content only. Not investment advice.